Document is current

Article History

Received: 19 February 2024

Accepted: 16 June 2024

First Online: 29 July 2024

Declarations

:

: Not applicable for this comment. All patients in the PROMINENT study gave written informed consent. The study was approved at participating centres by the responsible institutional review board or ethics committee, as applicable, and by regulatory authorities in the 24 countries where the trial was conducted.

: Not applicable.

: J-CF and JF-N report personal fees for consultancy from Kowa Company, Ltd. SY reports grants and personal fees from Kowa Company, Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Bayer Yakuhin, Ltd., MSD K.K., Takeda Pharmaceutical Company, Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Astellas Pharma Inc., Daiichi-Sankyo Company, Ltd., Astra Zeneka K.K., Kaken Pharmaceutical Co., Ltd., grants from Nippon Boehringer Ingelheim Co., Ltd., National Institute of Biomedical Innovation, Kyowa Medex Co., Ltd., Mochida Pharmaceutical Company, Ltd., Hayashibara Co., Ltd., Teijin Pharma Limited and Kissei; and personal fees from Ono Pharmaceutical Company, Ltd., Skylight Biotec, Inc., Pfizer, Astellas Amgen, Sanofi, and Aegerion In addition, M Yamashita has a patent PCT/JP2016/074402 (Assisting Method for the Diagnosis of Type III Hyperlipidemia) pending to Fujirebio & Osaka University, a patent PCT/JP2017/038766 (Method for Selecting Subject Needing Treatment for Dyslipidemia and Reagent for Such Selection) pending to Osaka University & Kyowa Medex Co., Ltd., and a patent PCT/JP2017/038715 (Method for Measuring Oxidized High-Density Lipoprotein) pending to Osaka University & Kyowa Medex Co.PL reports a research grant from Novartis and honoraria as a scientific advisory board member for Dalcor Pharmaceuticals, and provides unpaid consultancy for Amgen, AstraZeneca, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Pfizer, Sanofi-Regeneron, XBiotech Inc., Corvidia Therapeutics, IFM Therapeutics, Olatec Therapeutics, Medimmune and Esperion Therapeutics.KY reports grants and personal fees from Kowa Pharmaceutical Co, Astellas, AstraZeneca, MSD, Sanofi, Takeda, Pfizer, Mochida, and personal fees from Kowa Company, Astellas-Amgen Biopharm, and Bayer.TK is the recipient of a research grant from Kowa Company. YT reports research grants from the Alcon Research Institute, Manpei Suzuki Diabetic Foundation, Oguchi Foundation, and Kowa Life Science Foundation. PMR reports grants from Kowa, Inc, Novartis, and Pfizer. AZ reports honoraria for lectures from Abbott, Amgen, Sanofi and Mylan. MPH reports no conflict of interest.